Result:Weak· Market: Crashed
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 20.72 | 23.8% | 12.1% |
| Total Income | 20.80 | 26.3% | 14.8% |
| Expenditure | 20.31 | 23.2% | 14.4% |
| PBT | 0.49 | 72.2% | 29.2% |
| Net Profit | 0.36 | 4.6% | 41.1% |
| OPM | 11.33% | 1.53pp | 0.62pp |
| NPM | 1.71% | 0.39pp | 0.76pp |
| EPS | 0.08 | 46.7% | 93.8% |
Both revenue (-12.1% YoY) and adjusted net profit (-41.1% YoY) declined for this pharma name, with margins little changed, indicating a below-par quarter driven by top-line weakness rather than any offsetting cost or volume strength.
Informational and educational content only. Not investment advice.